Currentsierra health and lifePolicy 2026T0563W

Pneumatic Compression Devices

Defines medical necessity and coverage stance for pneumatic compression devices (PCDs) and intermittent pneumatic compression (IPC) for indications including lymphedema, chronic venous insufficiency, deep venous thrombosis prevention, and peripheral arterial disease; applies to UnitedHealthcare Commercial and Individual Exchange benefit plans.

Policy Summary

Payersierra health and life

PolicyPneumatic Compression Devices

Policy CodePolicy 2026T0563W

Change TypeTemplate update (administrative)

Effective DateJan 1, 2026

Next Review DateN/A

Key ActionSubmit supporting clinical records per InterQual and the member-specific benefit plan when requesting prior authorization.

SourceLink

POLICY UPDATE CHANGES

Template updated (Summary of Changes) on 01/01/2026.

Not coveredAPCD head/neck

Not coveredHigh-pressure PAD

Proven when criteria metIPC for DVT

Used as criteria sourceInterQual

2,876Key trial (CLOTS 3)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

General Coverage Stance

Coverage summary and linkage to objective criteria:

Overall coverage stance: Pneumatic compression devices are covered in certain circumstances for lymphedema or chronic venous insufficiency with edema and non-healing lower extremity ulcers, and IPC is covered for prevention of deep venous thrombosis when InterQual® clinical criteria are met; advanced APCDs for head/face/neck lymphedema and high-pressure rapid inflation PCDs for PAD are considered unproven and not medically necessary.

Refer to InterQual CP: Durable Medical Equipment, Pneumatic and other Powered Compression Devices for specific clinical criteria.

Stroke — Immobile patients

Evidence-supported indication from randomized controlled trial:

IPC for immobile acute stroke patients (CLOTS 3): IPC is effective to reduce DVT risk and improve 6-month survival in immobile patients after acute stroke when applied per trial protocols (applied up to 30 days or until mobility restored).as in CLOTS 3

Benefits accompanied by increased skin breaks and device-related adverse events; exclude patients with contraindications such as dermatitis, leg ulcers, severe edema, severe peripheral vascular disease, and congestive heart failure.

Perioperative / ICU

Perioperative and critically ill populations — mixed evidence:

IPC adjunct to pharmacologic prophylaxis in ICU/critically ill: A large randomized trial found no reduction in proximal lower-limb DVT when IPC was added to pharmacologic thromboprophylaxis in critically ill patients; adjunctive IPC should be used with caution and documented clinical justification is required.Arabi trial: no benefit (RR 0.93)

Document why adjunctive device is necessary over standard pharmacologic prophylaxis.

IPC for surgical patients: Systematic reviews and guideline statements indicate IPC may reduce DVT compared with no prophylaxis and that combining IPC with pharmacologic prophylaxis can reduce VTE for some surgical populations; evidence is heterogeneous and institution- and procedure-specific risk assessment should guide use.varies by study

Specify whether IPC is sole prophylaxis or adjunctive and follow guideline-based risk assessment (e.g., ASH, European perioperative guidance).

Venous ulcer / lymphedema

Venous leg ulcers, lymphedema, and chronic venous disease — adjunctive use:

IPC as adjunct for hard-to-heal venous ulcers or lymphedema: Randomized trials suggest IPC used as an adjunct to standard compression therapy can accelerate healing and reduce pain for some patients with large or chronic venous ulcers or lymphedema; consider IPC when standard compression is insufficient or not tolerated.study examples include Alvarez (n=52) showing faster median wound closure (141 vs 211 days)

Document prior trial of standard compression, rationale for adjunctive IPC, and monitoring plan; small sample sizes and methodological limitations noted.

PAD / CLTI

Peripheral arterial disease / chronic limb-threatening ischemia (CLTI):

IPC for PAD/CLTI: Guidelines suggest considering IPC in carefully selected patients with CLTI or PAD who are not candidates for revascularization to augment wound healing or relieve rest pain, but evidence quality is low to moderate and results are uncertain.Grade 2B (ESVS, AHA/ACC)

Document inability to perform revascularization and clinical rationale for a trial of IPC; acknowledge substantial uncertainty in benefit.

Covered Indications

Covered when clinical evidence or guideline-based indications are met

Prevention of DVT in immobile post-stroke patients: IPC is covered for immobile patients after acute stroke who meet trial-like criteria (admitted within days of stroke and immobile) as evidence (CLOTS 3) showed reduced DVT incidence and improved survival.as per clinical assessment and trial-like immobility criteria

CLOTS 3 inclusion/exclusion criteria and duration of IPC use inform patient selection.

Perioperative or postoperative prophylaxis: IPC may be used for postoperative patients at high bleeding risk where pharmacologic prophylaxis is contraindicated, or when pharmacologic prophylaxis is not given; in some high-risk surgical patients combined mechanical and pharmacologic prophylaxis may be appropriate.documented contraindication to pharmacologic prophylaxis or high bleeding risk

Follow institutional protocol and guideline recommendations (e.g., ASH, European guidelines).

Short-term outpatient immobilization (e.g., Achilles repair):

This policy designates that pneumatic compression devices (PCDs) are covered for selected indications when objective clinical criteria are met (see InterQual CP: Durable Medical Equipment, Pneumatic and other Powered Compression Devices). However, two device categories are explicitly considered not medically necessary: advanced intermittent pneumatic compression devices (APCDs) for lymphedema of the head, face, or neck and high-pressure, rapid inflation/deflation pneumatic compression devices for peripheral arterial disease (PAD). Coverage for other PCDs (including IPC for DVT prevention and devices for lymphedema or chronic venous insufficiency with non-healing lower-extremity ulcers) is contingent on meeting trial- or guideline-based indications and documentation requirements.

Clinical trials and protocols commonly excluded patients with local or systemic conditions that could contraindicate device use; examples cited in pivotal stroke trials include dermatitis, leg ulcers, severe edema, severe peripheral vascular disease, and congestive cardiac failure. When requesting coverage, document that these contraindications have been assessed and are absent or justified.

Mechanical prophylaxis is contraindicated in patients with suspected or proven peripheral arterial disease (PAD), peripheral arterial bypass grafting, or other local conditions where compression may cause harm (e.g., fragile skin, dermatitis, gangrene, recent skin graft). Evidence for PCD use in PAD/CLTI is inconsistent and device benefit on patient-centered outcomes is uncertain; high-pressure rapid inflation devices for arterial insufficiency are considered not medically necessary under this policy unless compelling, device-specific evidence and justification are provided.

The policy explicitly lists two not-medically-necessary designations: APCDs for head, face, or neck lymphedema due to insufficient evidence of efficacy and safety, and high-pressure, rapid inflation/deflation PCDs for arterial insufficiency/PAD because the evidence is inconsistent and insufficient to demonstrate benefit on patient-centered outcomes. Requests for these device types are subject to denial under this policy.

A large multicenter randomized trial of critically ill patients receiving pharmacologic thromboprophylaxis found no reduction in proximal lower-limb DVT with adjunctive IPC (Arabi et al.; 2003 patients). Therefore, routine use of adjunctive IPC in critically ill patients already receiving appropriate pharmacologic prophylaxis is not supported by this evidence and should be justified clinically if requested. Institutional and guideline recommendations favor mechanical prophylaxis primarily when pharmacologic prophylaxis is contraindicated or not provided.

Guidelines emphasize that when pharmacologic thromboprophylaxis is appropriate and not contraindicated, pharmacologic methods are preferred. Mechanical prophylaxis alone is not routinely supported for most hospitalized patients; use of IPC alone should be limited to patients with a documented contraindication to pharmacologic prophylaxis or other compelling clinical reasons. Prior authorization requests should state whether IPC is intended as sole prophylaxis or as an adjunct to pharmacologic therapy and include supporting justification.

Medical Necessity

DME Medical Necessity — InterQual linkage and contingent coverage

DME coverage is contingent on meeting InterQual clinical criteria; the following summarizes the equipment-level medical necessity statements in this policy:

Covered indications (summary): PCDs are considered proven and medically necessary for lymphedema or chronic venous insufficiency with edema and non-healing lower extremity ulcers when InterQual criteria are met; IPC is proven and medically necessary for DVT prevention when InterQual criteria are met.

See InterQual CP: Durable Medical Equipment, Pneumatic and other Powered Compression Devices for the specific clinical criteria and documentation requirements.

DME medical necessity examples — trial-derived necessity criteria

Examples of trial-derived medical necessity criteria (for authorization and documentation guidance):

IPC for immobile stroke patients: Patient is immobile after acute stroke (per trial definitions), has no contraindications to IPC, and IPC use is planned per protocol duration; documented rationale and monitoring plan required.

Coding

Applicable HCPCS CodesHCPCS

A4600	Sleeve for intermittent limb compression device, replacement only, each
E0650	Pneumatic compressor, nonsegmental home model
E0651	Pneumatic compressor, segmental home model without calibrated gradient pressure
E0652	Pneumatic compressor, segmental home model with calibrated gradient pressure
E0655	Nonsegmental pneumatic appliance for use with pneumatic compressor, half arm
E0658	Segmental pneumatic appliance for use with pneumatic compressor, integrated, 2 full arms and chest
E0659	Segmental pneumatic appliance for use with pneumatic compressor, integrated, head, neck and chest
E0660	Nonsegmental pneumatic appliance for use with pneumatic compressor, full leg
E0665	Nonsegmental pneumatic appliance for use with pneumatic compressor, full arm
E0666	Nonsegmental pneumatic appliance for use with pneumatic compressor, half leg

1–10 of 19

1/2

Device regulatory/product codemixed

JOW	FDA product code for pneumatic compression devices

Provider Actions and Prior Authorization

Prior Authorization

Prior authorization and plan checks

Prior authorization may be required by the plan. Confirm member-specific coverage and prior authorization requirements before device provision.

Affected codes: refer to Applicable Codes section for CPT/HCPCS — verify member plan and billing rules.
Step therapy / clinical criteria reference: InterQual® CP: Durable Medical Equipment, Pneumatic and other Powered Compression Devices (use InterQual subset for medical necessity).

Note

State adjunctive vs sole prophylaxis

State in the request whether the device is being prescribed as adjunctive therapy (combined with pharmacologic prophylaxis or other compression modalities) or as the sole prophylactic method. Where clinical guidance favors combination therapy, document rationale for sole-device use if chosen.

Adjunctive use: examples include IPC in addition to pharmacologic thromboprophylaxis for higher-risk patients or when evidence supports combined benefit.

Rental and Purchase Rules

Equipment	Payer rule / recommendation
Home pneumatic compressors and associated appliances (HCPCS E0650–E0652, E0660–E0669, E0670–E0673)
Rental vs purchase to be determined per member-specific benefit plan; follow the member's benefit terms and provider contract when requesting authorization

Equipment	Payer rule / recommendation
Intermittent pneumatic compression (IPC) devices (including calf/thigh sleeves and dual-action/segmental systems) — HCPCS examples: A4600, E0676
Rental or time-limited supply preferred for acute indications (e.g., postoperative immobilization, short-term adjunctive wound therapy); consider purchase when therapy is chronic or ongoing and documented as medically necessary. Document indication, prior conservative therapy, and intended duration per InterQual/plan requirements.

Equipment	Payer rule / recommendation
All pneumatic compression devices (PCDs and APCDs, including advanced systems cleared by FDA such as Flexitouch)
Coverage model (rental vs purchase) and payment rules determined per member-specific benefit plan and applicable mandates; verify member plan and provide documentation of device clearance and clinical indication when applicable.

Replacement

inv-41: IPC devices — replacement guidance

Replacement guidance for IPC garmentsNo explicit fixed replacement interval specified; replacement decisions based on clinical durability, infection/skin integrity concerns, and member benefit plan terms; consider replacement when garment integrity or hygiene is compromised

Replacement approach for acute vs chronic useFavor time-limited rental or supply for acute IPC use; for chronic ongoing therapy consider purchase or longer-term provision per plan and clinical need

Documentation to support replacementRecord clinical rationale for replacement (e.g., wear, loss, contamination, change in limb size), device model, and member-specific benefit plan authorization

Plan determinationPayer-specific rental vs purchase and replacement rules follow the member-specific benefit plan and applicable coding guidance

Infection / skin integrity triggerReplace garments promptly if there are device-related skin breaks, dermatitis, or other adverse skin events documented during use

Definitions

inv-28: PCD definition

TermPneumatic compression device (PCD): an air compressor unit that attaches to a garment or series of garments that sequentially inflate and deflate to apply pressure against the skin producing a treatment effect

FunctionApplies cyclic or sequential pressure to limbs to treat edema, lymphedema, chronic wounds, or reduce venous stasis

Device complexity rangeRanges from traditional single- or multi-chambered devices with limited adjustability to advanced programmable systems with expanded garment options

inv-29: IPC definition

TermIntermittent pneumatic compression (IPC): inflatable sleeves wrapped around the legs (calf and/or thigh) that inflate sequentially to compress the limbs and enhance venous flow

Mechanism

Documentation Requirements

Prior Authorization

Submit supporting clinical records per InterQual and plan prior authorization processes

Submit all supporting clinical records required by InterQual criteria and the member's plan prior authorization process when requesting coverage; InterQual may be used as the objective evidence-based tool to support medical necessity determinations.

Include clinical evidence mapped to InterQual CP: Durable Medical Equipment, Pneumatic and other Powered Compression Devices.

Documentation Required

Document indication, prior conservative therapy, contraindication screening, duration, and monitoring plan

Record the indication (e.g., immobility after acute stroke, chronic venous ulcer refractory to standard compression, CLTI not amenable to revascularization), prior conservative therapies tried, screening for contraindications, planned daily duration of device use, and a monitoring plan for skin integrity and adverse events.

CLOTS 3 and wound trials documented immobility criteria, duration of IPC use, and monitoring for skin breaks and falls—use similar elements in clinical records.

Background

Pneumatic compression devices (PCDs) are air-compressor units attached to garments that sequentially inflate and deflate to apply pressure against the skin and promote fluid movement. Intermittent pneumatic compression (IPC) uses inflatable sleeves for the calf and/or thigh to enhance venous return and reduce venous stasis; devices range from simple IPC sleeves to advanced pneumatic systems with specialized garments and programmable cycles for lymphedema management.

Not Covered / Exclusions

Not covered under this policy are advanced pneumatic compression systems (APCDs) for lymphedema of the head, face, or neck and high-pressure, rapid inflation/deflation PCDs for arterial insufficiency/PAD. The policy cites insufficient or inconsistent evidence for APCDs in head/neck lymphedema and lack of definitive safety and efficacy data for high-pressure devices in PAD. FDA clearance of a device (e.g., Flexitouch) is informational but does not by itself establish coverage; requests must still meet the policy's clinical criteria and plan terms.

Policy Summary

Payersierra health and life

PolicyPneumatic Compression Devices

Policy CodePolicy 2026T0563W

Change TypeTemplate update (administrative)

Effective DateJan 1, 2026

Next Review DateN/A

Key ActionSubmit supporting clinical records per InterQual and the member-specific benefit plan when requesting prior authorization.

SourceLink

On This Page

Short-term IPC during periods of immobilization may reduce early DVT risk in some postoperative outpatients not receiving pharmacologic anticoagulation, with benefit demonstrated at early time points in RCTs.

intervention period per trial (e.g., ~6 hrs/day for 2 weeks)

Consider patient age and baseline risk factors when selecting therapy.

Lymphedema treatment with advanced systems: Advanced pneumatic compression systems cleared for lymphedema (including head and neck) may be used for treatment when clinically indicated and device-specific FDA clearance exists; coverage is subject to benefit plan terms and documentation.device-specific clearance and clinical indication documented

FDA clearance alone is informational; payer coverage follows plan terms and documented medical necessity.

as per CLOTS 3 enrollment

Supported by RCT evidence (CLOTS 3) showing reduced DVT and improved survival; note increased device-related skin breaks reported in trials.

DME medical necessity — equipment medically necessary when evidence- or guideline-supported indications are met

Equipment is medically necessary when used for evidence- or guideline-supported indications and documented per plan requirements:

Post-stroke immobility: Patient admitted shortly after acute stroke and immobile as defined in pivotal trials; IPC applied per protocol to reduce DVT risk.meets trial-like immobility criteria

CLOTS 3 provides primary evidence.

High bleeding risk surgical patients: Patient undergoing major surgery with high bleeding risk or contraindication to anticoagulation; IPC used as mechanical prophylaxis.documented contraindication to pharmacologic prophylaxis

Follow institutional protocol and guideline recommendations.

Short-term outpatient immobilization: Patients immobilized after procedures (e.g., Achilles tendon repair) who are not receiving pharmacologic anticoagulation may receive IPC for the early postoperative period to reduce early DVT risk.treatment period similar to studies (e.g., first 2 weeks)

Consider age and other risk factors.

Lymphedema treatment with cleared device: Use of an FDA-cleared advanced pneumatic compression system for treatment of lymphedema when prescribed by a clinician and supported by clinical documentation.device clearance and clinical indication documented

Coverage subject to plan terms and required documentation.

Sole prophylaxis: may be appropriate when pharmacologic prophylaxis is contraindicated (e.g., high bleeding risk) — cite clinical assessment and guideline-based indication.

Documentation Required

Consider conservative compression before IPC

Conservative compression options (elastic compression stockings, inelastic bandages, adjustable compression garments) should be considered and documented before intermittent pneumatic compression (IPC) for venous leg ulceration and symptomatic chronic venous disease when appropriate. If IPC is used because other compression modalities are unavailable, unsuitable, or have failed, document prior trials and outcomes.

Document trial of conservative compression: type, duration, adherence, and clinical response (e.g., wound size, edema reduction).
If modified compression is used for mixed arterial/venous disease, document ankle pressure and rationale for pressure selection (<40 mmHg when indicated).

Denial Risk

Denial triggers

Denial triggers — items that may lead to non-coverage or denial if present or not documented.

Advanced devices for head/face/neck lymphedema (e.g., Flexitouch) when requested for head/neck indications — considered unproven and not medically necessary for these sites.
High-pressure, rapid inflation/deflation pneumatic devices for peripheral arterial disease (PAD) — considered unproven and not medically necessary.
Requests that do not reference or meet InterQual® clinical criteria for the requested indication.
Failure to provide member-specific plan benefits or prior authorization when required.

Denial Risk

IPC contraindications from trials and guidance

IPC contraindications and conditions noted in clinical trials and guidelines that should be reviewed and documented. Presence of these contraindications may warrant denial or alternative therapy.

Suspected or proven peripheral arterial disease or peripheral arterial bypass grafting.
Peripheral neuropathy or other sensory impairment preventing safe use.
Local conditions at risk for damage (fragile skin, dermatitis, gangrene, recent skin grafts, severe leg edema).
Severe peripheral vascular disease, congestive cardiac failure (per trial exclusions).
Major limb deformity or unusual leg size/shape preventing correct fit.

Documentation Required

Medical record requirements (may be required)

Medical record and documentation requirements that may be requested on review to determine medical necessity.

Member-specific benefit plan and any applicable state/federal mandates must be checked and referenced.
Clinical indication with supporting history and exam findings.
Prior conservative therapy details (e.g., compression stockings/bandages): type, duration, adherence, and response.
If adjunctive to pharmacologic prophylaxis: documentation of pharmacologic agent, dose, start date, and rationale for combination.
If sole prophylaxis: documentation of contraindication to pharmacologic prophylaxis (detailed bleeding risk assessment).
For venous leg ulcers: wound measurements, duration, prior wound care, and healing progress.
For head/neck lymphedema requests: document why covered alternative treatments are insufficient; note that head/neck IPC is generally considered unproven for coverage purposes (Flexitouch clearance is informational only).
Device specifics: model, pressure settings, inflation cycle characteristics, and justification if high-pressure/rapid-inflation device is requested.

Documentation Required

Suggested documentation elements from trials

Suggested documentation elements drawn from clinical trials and guideline evidence to support medical necessity reviews.

For prophylaxis trials (e.g., CLOTS, Arabi et al.): duration and hours/day of IPC use, monitoring plan, and expected duration of therapy.
Outcome measures: ultrasound or imaging results for DVT surveillance when used in trials; record of DVT/PE events or screening findings.
Adverse events or device-related complications (e.g., skin breakdown, falls) and monitoring/mitigation plans.
For ulcer care trials/guidelines: baseline and follow-up wound dimensions, ulcer staging, ankle-brachial index (ABI) or toe pressures if arterial disease suspected, and documentation of arterial status before compression therapy.
If requesting combined therapy, reference evidence supporting additive benefit (e.g., Cochrane review showing reduced DVT/PE with combined IPC and pharmacologic prophylaxis).

Documentation Required

Required documentation and plan check

Required documentation and plan check at time of submission — the plan will verify member benefits and applicable criteria; missing information may delay or deny coverage.

Confirm and include member-specific benefit verification and prior authorization number if applicable.
Attach clinical notes supporting indication, prior treatments, and contraindications to alternative therapies.
Include device prescription with clear device description (model, pressure profile) and clinician signature.
Provide objective measures when relevant (ABI, wound measurements, ultrasound results).
If InterQual® criteria are referenced, indicate which InterQual subset and how the member meets each required element.
Be prepared to supply additional records on request; absence of requested documentation is a common reason for denial.

Step Therapy

Step therapy reference — InterQual®

Step therapy and clinical criteria reference to apply when reviewing requests.

Use InterQual® CP: Durable Medical Equipment, Pneumatic and other Powered Compression Devices for medical necessity determination and step/sequence requirements.
If step therapy requires trial of conservative compression or pharmacologic prophylaxis first, document trial results and rationale for proceeding to IPC.
Where institutional or specialty guidelines recommend adjunctive use (e.g., combined pharmacologic and mechanical prophylaxis), document applicability to the individual member.

inv-42: N/A

Not applicable entryN/A

Plan referenceWhen a replacement policy is not specified in this document, reference the member-specific benefit plan and applicable mandates

Provider actionVerify member-specific coverage and authorization requirements before replacement request

Inflation may occur distally then proximally (sequential) to increase venous return and reduce stasis; thought to stimulate intrinsic fibrinolytic factors

Clinical roleUsed for prevention of DVT in selected immobile patients (e.g., post-stroke per CLOTS 3) and for prophylaxis/treatment in other settings per guideline and trial evidence

inv-30: APCD definition

TermAdvanced intermittent pneumatic compression device (APCD): a more complex, programmable PCD with expanded garment options and treatment programmability for conditions such as lymphedema (including head/neck) and chronic wounds

Regulatory noteAPCDs are FDA-cleared devices (e.g., Flexitouch Plus received FDA clearance 12/20/2020) but clearance alone is informational and not a basis for coverage

Policy stanceAPCDs for head/face/neck lymphedema are considered unproven and not medically necessary per this policy unless plan-specific terms indicate otherwise

inv-31: Dual-action / sequential IPC definition

TermDual-action / sequential IPC: devices that provide sequential or dual-mode compression (e.g., distal-to-proximal sequencing or combined modes) aimed at improving venous return and reducing limb volume

Clinical evidenceStudied as adjuncts in chronic venous disease and venous ulcer trials with some trials showing volume reduction or accelerated healing when added to standard compression

Typical useUsed where enhanced or targeted compression patterns are desired (e.g., obese patients or hard-to-heal ulcers) as adjunct to standard compression therapy

inv-32: Arterial IPC (for CLI/CLTI) definition

TermArterial IPC (for CLI/CLTI): IPC devices intended to augment arterial inflow or support wound healing and relieve ischemic rest pain in patients with chronic limb-threatening ischemia when revascularization is not an option

Guideline positionESVS and AHA/ACC guidelines state arterial IPC may be considered in carefully selected CLTI patients not amenable to revascularization (Grade 2B)

Evidence certaintyEvidence is limited and of low-to-moderate quality; document inability to revascularize and clinical rationale when used

inv-33: Intermittent pneumatic compression (IPC) — general

TermIntermittent pneumatic compression (IPC) — general: a mechanical device that cyclically inflates and deflates garments around the limbs to promote venous return and reduce venous thromboembolism risk

IndicationsProven for DVT prevention in selected immobile post-stroke patients (e.g., CLOTS 3) and used for perioperative prophylaxis or adjunctive therapy in selected scenarios

Adverse events and exclusionsIPC use increases device-related skin breaks in trials (e.g., CLOTS 3) and patients with dermatitis, leg ulcers, severe edema, severe peripheral vascular disease, or congestive heart failure were excluded from key trials

inv-34: Advanced pneumatic compression system (e.g., Flexitouch)

TermAdvanced pneumatic compression system (example: Flexitouch): an FDA-cleared pneumatic system with specialized programmable garments intended for lymphedema treatment, including head and neck applications

Clearance exampleFlexitouch Plus System received FDA clearance on December 20, 2020 (manufacturer: Tactile Systems Technology, Inc.)

Coverage noteDespite FDA clearance for head/neck use, APCDs for head/face/neck lymphedema are considered unproven and not medically necessary under this policy unless plan terms specify otherwise

Note

Reference member-specific benefit plan and federal/state mandates on authorization requests

When requesting authorization, reference the member-specific benefit plan and applicable federal/state mandates; the member's plan document governs coverage decisions and may impose additional requirements.

Policies note that FDA clearance alone is informational and does not guarantee coverage; plan terms prevail.